GEN Exclusives

More »

GEN Poll

More »
Jul 18, 2011

Clinical Trial Strategy

Unlike large biopharma firms, most small biotech companies usually have their fortunes riding on only a single drug. If a small firm’s product fails a Phase II trial, do you think the smart move is to keep working on its product candidate instead of entirely scrapping the project?

If a firm’s only candidate fails a Phase II trial, should it push on with development?

Yes
 
  33.8%
No
 
  43.2%
Undecided
 
  23.0%

More Polls » View Results »

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?